Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,546 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,539 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00070967 | Acupuncture to Improve Quality of Life in Patients With Advanced Cancer | completed | Phase 2 | 40 | National Center for Complementary and Integrative Health (NCCIH)NIH | 1 | Aug 18, 2006 | clinicaltrials |
| NCT00108875 | Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer | unknown | Phase 1 / Phase 2 | 70 | Julius-Maximilians UniversityOTHER | 1 | Jul 28, 2006 |
| clinicaltrials |
| NCT00275353 | Effectiveness of an Individualized Symptom Education Program (ISEP) | completed | Phase 2 | 144 | University of TorontoOTHER | 1 | May 26, 2006 | clinicaltrials |
| NCT00179725 | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | terminated | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Apr 12, 2006 | clinicaltrials |
| NCT00188383 | Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy | unknown | Phase 1 / Phase 2 | 132 | University Health Network, TorontoOTHER | 1 | Mar 14, 2006 | clinicaltrials |
| NCT00103428 | Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 69 | Cell GenesysINDUSTRY | 1 | Feb 2, 2006 | clinicaltrials |
| NCT00199680 | Interest of PET Imagery With 18-FDG in the Extension Assessment of the Cervical Cancer | unknown | Phase 2 | 42 | University Hospital, LimogesOTHER | 1 | Feb 1, 2006 | clinicaltrials |
| NCT00151645 | Efficacy of Activated Lymphocytes in Renal Cell Carcinoma. | terminated | Phase 2 | 36 | Rennes University HospitalOTHER | 1 | Jan 2, 2006 | clinicaltrials |
| NCT00179738 | A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer. | terminated | Phase 2 | 40 | Celgene CorporationINDUSTRY | 1 | Nov 23, 2005 | clinicaltrials |
| NCT00231075 | Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV | completed | Phase 2 | 75 | ARCAGY/ GINECO GROUPOTHER | 1 | Nov 3, 2005 | clinicaltrials |
| NCT00215345 | A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer | unknown | Phase 2 | 66 | Department of Veterans Affairs, New JerseyFED | 1 | Sep 22, 2005 | clinicaltrials |
| NCT00218205 | A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer | unknown | Phase 2 | 28 | Department of Veterans Affairs, New JerseyFED | 1 | Sep 22, 2005 | clinicaltrials |
| NCT00164437 | CD-ROM Intervention for Prostate Cancer Screening | completed | Phase 2 / Phase 3 | 554 | Centers for Disease Control and PreventionFED | 1 | Sep 14, 2005 | clinicaltrials |
| NCT00140374 | Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer) | completed | Phase 1 / Phase 2 | 36 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00140387 | Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®) | completed | Phase 1 / Phase 2 | 20 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00140400 | Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 50 | Cell GenesysINDUSTRY | 0 | Sep 1, 2005 | clinicaltrials |
| NCT00116155 | Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | — | Cell GenesysINDUSTRY | 0 | Jun 28, 2005 | clinicaltrials |
| NCT00061126 | ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body | completed | Phase 2 | 50 | AbgenixINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Aug 18, 2006source: clinicaltrials